Transfusion-transmitted hepatitis E: What we know so far?

doi:10.3748/wjg.v28.i1.47

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 1

This Article

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11660)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

874

WORD

334

HTML

5883

Figures (1-1)

689

Tables (1-4)

857

Sum=8637

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

425

Download

747

Sum=1172

Publishing Process of This Article

Item

Count

Browse

649

Download

1206

Sum=1855

Jan 7, 2022 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Jan 7, 2022; 28(1): 47-75
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.47

Transfusion-transmitted hepatitis E: What we know so far?

Carmen Ka Man Cheung, Sunny Hei Wong, Alvin Wing Hin Law, Man Fai Law

Carmen Ka Man Cheung, Man Fai Law, Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong 852, China

Sunny Hei Wong, Institute of Digestive Disease and Department of Medicine and Therapeutics, the Chinese University of Hong Kong, Hong Kong 852, China

Sunny Hei Wong, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore

Alvin Wing Hin Law, West Island School, Hong Kong 852, China

Author contributions: Cheung CKM contributed to acquisition, analysis and interpretation of data/references; drafted and approved the manuscript; Wong SH contributed to analysis, interpretation of data/references; revised critically and approved the manuscript; Law AWH contributed to analysis of data/references and approved the manuscript; Law MF contributed to acquisition, analysis and interpretation of data/references, and drafted and approved the manuscript.

Conflict-of-interest statement: The authors declare no conflict of interest.

Corresponding author: Man Fai Law, MRCP, Doctor, Medicine and Therapeutics, Prince of Wales Hospital, 30-32 Ngai Shing Street, Shatin, Hong Kong 852, China. mflaw99@yahoo.com.hk

Received: April 10, 2021
Peer-review started: April 10, 2021
First decision: June 24, 2021
Revised: July 16, 2021
Accepted: December 22, 2021
Article in press: December 22, 2021
Published online: January 7, 2022
Processing time: 264 Days and 19.1 Hours

Core Tip

Core Tip: Transfusion-transmitted hepatitis E virus (HEV) is an emerging global health concern. In immunocompromised patients, chronic HEV infection increases the risk of liver cirrhosis. The prevalence of viremia and anti-HEV immunoglobulin G in asymptomatic blood donors varies widely between countries but even low concentrations of HEV in blood components are infectious, and in most countries blood donations are not routinely screened for HEV. Treatment of persistent infection includes modification of the immunosuppressant regimen followed by ribavirin. The need for screening of HEV in all blood donations remains controversial. Strategies to reduce de novo HEV infection should also be emphasized.